Achievement of NKF/K-DOQI Recommended Target Values for Bone and Mineral Metabolism in Incident Hemodialysis Patients: Results of the FARO-2 Cohort

被引:16
作者
Cozzolino, Mario [1 ]
Messa, Piergiorgio [2 ]
Brancaccio, Diego [3 ]
Cannella, Giuseppe [4 ]
Bolasco, Piergiorgio [5 ]
Di Luca, Marina [6 ]
Costanzo, Anna Maria [7 ]
Paparatti, Umberto di Luzio [7 ]
Festa, Vincenzo [7 ]
Gualberti, Giuliana [7 ]
Mazzaferro, Sandro [8 ]
机构
[1] Univ Milan, Dept Hlth Sci, San Paolo Hosp, Div Renal, IT-20142 Milan, Italy
[2] Fdn Ca Granda IRCCS Policlin, Milan, Italy
[3] Dialysis Unit Simone Martini, Milan, Italy
[4] San Martino Hosp, Dept Nephrol, Genoa, Italy
[5] ASL Cagliari, Terr Nephrol & Dialysis Unit, Cagliari, Italy
[6] Osped Riuniti Marche Nord, UOC Nephrol Dialysis, Pesaro, Italy
[7] AbbVie SrL Italy, Latina, Italy
[8] Univ Roma La Sapienza, Dipartimento Sci Cardiovasc Resp Nefrol & Geriatr, I-00185 Rome, Italy
关键词
Mineral Bone Disorders; NKF/K-DOQI; Incident haemodialysis; Survival; CHRONIC KIDNEY-DISEASE; VITAMIN-D; SECONDARY HYPERPARATHYROIDISM; PARATHYROID-HORMONE; DIALYSIS PATIENTS; MORTALITY RISK; CARDIOVASCULAR-DISEASE; PHOSPHATE PRODUCT; ORAL PARICALCITOL; PRACTICE PATTERNS;
D O I
10.1159/000365386
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Mineral Bone Disorders (MBD) is prevalent in hemodialysis (HD) patients and associated with increased cardiovascular mortality. The FARO-2 study evaluated the achievement of the NKF/K-DOQI guidelines on recommended target values for serum calcium (Ca), phosphorous (P) and intact parathyroid hormone (PTH) levels on survival in incident HD patients. Methods: Data were collected by questionnaire from 568 incident HD patients followed prospectively over a 3-year period from 26 Italian dialysis units. The cumulative probability of time-to-death for CKD-MBD treatment characteristics was determined by the Kaplan-Meier curves. Results: Serum PTH levels (median values at 6 months vs. 36 months; 225 vs. 254 pg/ml), Ca (8.8 vs. 8.9 g/dl) and P (5.1 vs. 4.8 mg/dl) were not significantly different at 6 months versus follow-up. The majority of incident HD patients (60-70%) who were followed up for 36 months did not achieve the NKF/K-DOQI recommended target values. Survival rates were higher in patients on target for three parameters versus patients off target (survival at 24 months: at target 95.7% (95% CI: 84.0-98.9) versus not on target 71.1% (95% CI: 66.3-75.4, p < 0.01)). The 30.1% of patients on target for three MBD parameters at least once during the follow-up period had better survival rates compared to those not reaching these targets (survival at 24 months: at least once 88.0% (95% CI: 81.9-92.1); 67.7% (95% CI: 61.9-72.8, p < 0.01)). Conclusion: Our findings indicate that incident HD patients who achieved target levels (for three MBD parameters) for at least one visit have a lower risk of mortality. (C) 2014 S. Karger AG, Basel
引用
收藏
页码:37 / 45
页数:9
相关论文
共 51 条
[1]  
Arenas MD, 2007, J NEPHROL, V20, P453
[2]   Mineral metabolism, mortality, and morbidity in maintenance hemodialysis [J].
Block, GA ;
Klassen, PS ;
Lazarus, JM ;
Ofsthun, N ;
Lowrie, EG ;
Chertow, GM .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (08) :2208-2218
[3]   Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study [J].
Block, GA ;
Hulbert-Shearon, TE ;
Levin, NW ;
Port, FK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (04) :607-617
[4]   Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism [J].
Block, Geoffrey A. ;
Zeig, Steven ;
Sugihara, Jared ;
Chertow, Glenn M. ;
Chi, Eric M. ;
Turner, Stewart A. ;
Bushinsky, David A. .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2008, 23 (07) :2311-2318
[5]   Predictors of early mortality among incident US hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS) [J].
Bradbury, Brian D. ;
Fissell, Rachel B. ;
Albert, Justin M. ;
Anthony, Mary S. ;
Critchlow, Cathy W. ;
Pisoni, Ronald L. ;
Port, Friedrich K. ;
Gillespie, Brenda W. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 2 (01) :89-99
[6]   Secondary Hyperparathyroidism in Chronic Dialysis Patients: Results of the Italian FARO Survey on Treatment and Mortality [J].
Brancaccio, Diego ;
Cozzolino, Mario ;
Cannella, Giuseppe ;
Messa, Piergiorgio ;
Bonomini, Mario ;
Cancarini, Giovanni ;
Caruso, Maria Rosa ;
Cascone, Carmelo ;
Costanzo, Anna Maria ;
Paparatti, Umberto di Luzio ;
Mazzaferro, Sandro .
BLOOD PURIFICATION, 2011, 32 (02) :124-132
[7]   Drug Insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease [J].
Brown, Alex J. ;
Slatopolsky, Eduardo .
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2007, 3 (02) :134-144
[8]  
Capuano A, 2009, J NEPHROL, V22, P59
[9]  
Cozzolino M, 2012, NEPHROL DIAL TRANSPL, V27, pii1
[10]   VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH ≤ 150 pg/mL: results of the Italian FARO Survey [J].
Cozzolino, Mario ;
Brancaccio, Diego ;
Cannella, Giuseppe ;
Messa, Piergiorgio ;
Gesualdo, Loreto ;
Marangella, Martino ;
LoDeserto, Cosimo ;
Pozzato, Marco ;
Rombola, Giuseppe ;
Costanzo, Anna Maria ;
Paparatti, Umberto di Luzio ;
Mazzaferro, Sandro .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 (09) :3588-3594